MolMed S.p.A. is a medical biotechnology company focused on discovery, R&D, and clinical validation of innovative therapies for the treatment of cancer.
MolMed’s approach to cancer is based on an integrated strategy that provides both drugs effectively targeting the growing tumour mass in the acute stage, and highly selective therapies to eliminate residual disease.
Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is a mature company covering all functions, from discovery to proof of clinical activity.
MolMed is located in Milan, Italy, within the San Raffaele Biomedical Science Park, which includes the renowned research hospital and scientific institute, along with several thriving biotechnology companies, and a private university. This location offers crucial advantages: thanks to preferential access, MolMed can fully exploit the privilege of complementing its own R&D resources with the cutting-edge technological and clinical resources of its host institution. The San RaffaeleScientific Institute counts over 500 scientists, with almost 600 publications in international journals in 2006; and the hospital is the largest Italian private clinical centre, with over 1400 beds and more than 100 clinical studies running each year.
|
;)
